Lynx1 Capital Management L.P. 13F annual report
Lynx1 Capital Management L.P. is an investment fund managing more than $277 billion ran by Weston Nichols. There are currently 17 companies in Mr. Nichols’s portfolio. The largest investments include Merus N.V and Stoke Therapeutics, together worth $141 billion.
$277 billion Assets Under Management (AUM)
As of 12th August 2024, Lynx1 Capital Management L.P.’s top holding is 1,206,707 shares of Merus N.V currently worth over $71.4 billion and making up 25.8% of the portfolio value.
Relative to the number of outstanding shares of Merus N.V, Lynx1 Capital Management L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 5,185,191 shares of Stoke Therapeutics worth $70.1 billion, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Gh Research Plc worth $46.3 billion and the next is C4 Therapeutics worth $31.8 billion, with 6,880,527 shares owned.
Currently, Lynx1 Capital Management L.P.'s portfolio is worth at least $277 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Lynx1 Capital Management L.P.
The Lynx1 Capital Management L.P. office and employees reside in San Juan, Puerto Rico. According to the last 13-F report filed with the SEC, Weston Nichols serves as the Chief Investment Officer at Lynx1 Capital Management L.P..
Recent trades
In the most recent 13F filing, Lynx1 Capital Management L.P. revealed that it had opened a new position in
Cullinan Therapeutics Inc and bought 377,323 shares worth $6.58 billion.
The investment fund also strengthened its position in Stoke Therapeutics by buying
1,488,371 additional shares.
This makes their stake in Stoke Therapeutics total 5,185,191 shares worth $70.1 billion.
Stoke Therapeutics dropped approximately 0.1% in the past year.
On the other hand, there are companies that Lynx1 Capital Management L.P. is getting rid of from its portfolio.
Lynx1 Capital Management L.P. closed its position in Alpine Immune Sciences Inc on 19th August 2024.
It sold the previously owned 2,253,183 shares for $89.3 billion.
Weston Nichols also disclosed a decreased stake in Merus N.V by 0.2%.
This leaves the value of the investment at $71.4 billion and 1,206,707 shares.
One of the smaller hedge funds
The two most similar investment funds to Lynx1 Capital Management L.P. are Moerus Capital Management and Bbjs Financial Advisors. They manage $277 billion and $277 billion respectively.
Weston Nichols investment strategy
Lynx1 Capital Management L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 68.0% of
the total portfolio value.
The fund focuses on investments in the United States as
47.1% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
24% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $308 million.
The complete list of Lynx1 Capital Management L.P. trades based on 13F SEC filings
These positions were updated on August 19th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Alpine Immune Sciences Inc |
Closed
2,253,183
|
$89,316,174,000 | |
| Merus N.V |
20.03%
1,206,707
|
$71,400,853,000 | 25.76% |
| Stoke Therapeutics, Inc. |
40.26%
5,185,191
|
$70,051,931,000 | 25.27% |
| Gh Research Plc |
19.82%
3,966,726
|
$46,252,025,000 | 16.69% |
| C4 Therapeutics, Inc. |
89.30%
6,880,527
|
$31,788,035,000 | 11.47% |
| Tscan Therapeutics Inc |
No change
5,224,600
|
$30,563,910,000 | 11.03% |
| Silence Therapeutics plc |
Closed
526,642
|
$11,375,467,000 | |
| Autolus Therapeutics plc |
Closed
1,390,160
|
$8,869,221,000 | |
| Cullinan Therapeutics Inc |
Opened
377,323
|
$6,580,513,000 | 2.37% |
| Kinnate Biopharma Inc. |
Closed
1,981,106
|
$5,269,742,000 | |
| Allogene Therapeutics Inc |
Opened
2,228,295
|
$5,191,927,000 | 1.87% |
| Longboard Pharmaceuticals In |
Opened
167,317
|
$4,522,579,000 | 1.63% |
| Passage Bio Inc |
4.37%
5,057,629
|
$4,016,769,000 | 1.45% |
| Cabaletta Bio Inc |
76.37%
492,103
|
$3,680,930,000 | 1.33% |
| Nektar Therapeutics |
Closed
2,068,842
|
$1,932,712,000 | |
| iBio Inc |
40.13%
840,763
|
$1,774,010,000 | 0.64% |
| Pieris Pharmaceuticals Inc |
Closed
8,779,162
|
$1,608,342,000 | |
| Bionomics Limited |
26.37%
599,673
|
$459,949,000 | 0.17% |
| Pieris Pharmaceuticals Inc |
Opened
43,499
|
$426,756,000 | 0.15% |
| Kiniksa Pharmaceuticals Intl |
Opened
9,500
|
$177,365,000 | 0.06% |
| Centessa Pharmaceuticals Plc |
No change
17,400
|
$157,122,000 | 0.06% |
| Korro Bio Inc |
Opened
3,800
|
$128,706,000 | 0.05% |
| VYNE Therapeutics Inc. |
Opened
16,194
|
$31,902,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 23 holdings | |||
Hedge funds similar to Lynx1 Capital Management L.P.
- Barry Investment Advisors
- Sof Ltd
- Pathway Advisers
- Portland Investment Counsel Inc
- Northcape Wealth Management
- Cardinal Strategic Wealth Guidance
- Bbjs Financial Advisors
- Moerus Capital Management
- Fortis Capital Advisors
- Lfl Advisers
- Legacy Capital California
- Quantedge Capital Pte Ltd
- Thomist Capital Management, L.P.
- Truefg